A shareholder has filed a lawsuit against officers and directors of Novavax Inc. on Wednesday, claiming they misled the public about the likelihood of developing and selling a vaccine for COVID-19 to reap millions in personal gains.

Maryland-based Novavax is the second company to be sued in the Court of Chancery for leading investors to believe vaccine testing and production was going better than it was, with similar allegations made 16 months ago against Sorrento Therapeutics Inc.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]